NewsFrequency Therapeutics prepares to advance first-in-class drug candidate FX-322 into Phase 2a study…
NewsOtonomy Expands Recruiting Locations for Phase 1/2 Clinical Trial of OTO-313 in Patients with Subjective Tinnitus
NewsThe Truth About Tinnitus Habituation: Deficient Sensory Gating Could Explain Why Many Tinnitus Victims Do Not Habituate
NewsFrequency Therapeutics licenses FX-322 outside U.S. to Astellas Pharma for $80M. Both companies will work on global clinical trials for the treatment and coordinate launch efforts.
NewsNew Treatment-Related Research from Dr. Susan Shore: Mechanisms of Noise-Induced Tinnitus: Insights from Cellular Studies
NewsResearch Roundup: 20+ field reports from the Tinnitus Research Initiative (TRI) 2019 Conference in Taipei
NewsNew findings support the view that tinnitus could be a proprioceptive illusion related to the middle-ear muscles
NewsDrug to reduce brain inflammation cured tinnitus in mice – paving the way towards a pill for humans
NewsSound Pharmaceuticals Completes Phase 2 Study of SPI-1005 for the Treatment of Tinnitus and Vertigo in Patients with Meniere’s Disease
NewsUPDATE: Frequency Therapeutics to present newest FX-322 clinical trial results on September 17, 2019 [early]
NewsWhat’s really going on in the world of tinnitus research? Seven insights from the #TRI2019 Conference…
NewsNew study results raise serious concerns about effectiveness of Tinnitus Retraining Therapy (TRT)
NewsFrequency Therapeutics to present major FX-322 update on September 18, 2019 at AAO-HNSF Annual Meeting in New Orleans
NewsPossible tinnitus remedy uncovered during ethnobotanical study of medicinal plants used in Central Macedonia, Greece
NewsMajor analysis of tinnitus patients’ hearing loss points to “stochastic resonance” (SR) as root cause of tinnitus
NewsNeuromod Broadens Senior Leadership Team in Preparation for Global Commercialisation of Lenire™ Tinnitus Treatment
NewsFirst study investigating the relationship between chronic tinnitus and peripheral blood derived BDNF/ GDNF promoter methylations
NewsNEUROMOD VIDEO: “New Treatment for Tinnitus Evaluated in over 500 Patients” [Dr. Hubert Lim presentation]
NewsPhase 1/2 clinical trial of OTO-313 (single intratympanic injection) in patients with subjective tinnitus is now recruiting
NewsOtonomy Initiates Phase 1/2 Clinical Trial to evaluate the therapeutic potential of OTO-313 in patients with tinnitus
NewsMichigan Medicine researchers studying tinnitus reach final round in STAT Madness (“March Madness” of science) tournament
NewsUpdate from Susan Shore: “we were able to reduce the spontaneous firing of these neurons, which resulted in reduction of the tinnitus”
NewsFrequency Therapeutics plans on asking the FDA to fast track FX-322, citing recent studies that link hearing loss to other diseases like depression and dementia
NewsAnother upcoming Neuromod Device podium abstract “from the future” (March 29, 2019) – with some interesting implications…
NewsFrequency Therapeutics Completes Enrollment in Single Dose Safety Trial to Evaluate FX-322, a First-in-Class Drug Candidate for Hearing Restoration
NewsCould this new jab mean the end of hearing aids? Experimental treatment injected into the ear could restore hearing by growing new ‘hair’ cells
NewsFrequency Therapeutics’ First-in-Human Safety Study of FX-322 for Hearing Restoration Achieves All Endpoints
